Antipsychotic-induced weight gain: A review of the literature

Journal of Clinical Psychiatry

Volumn 62, Issue SUPPL. 7, 2001, Pages 22-31

  Allison, D B ^a   Casey, D E ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ADRENERGIC RECEPTOR; AMANTADINE; ANTIOBESITY AGENT; CHLORPROMAZINE; CLOZAPINE; DOPAMINE RECEPTOR; FENFLURAMINE; FLUPHENAZINE; HALOPERIDOL; HISTAMINE H1 RECEPTOR; MOLINDONE; MUSCARINIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; PHENTERMINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN RECEPTOR; SIBUTRAMINE; TETRAHYDROLIPSTATIN; THIORIDAZINE; ZIPRASIDONE;

BEHAVIOR THERAPY; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; META ANALYSIS; OBESITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; ANTIPSYCHOTIC AGENTS; BEHAVIOR THERAPY; BENZODIAZEPINES; BODY MASS INDEX; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; PATIENT COMPLIANCE; PIRENZEPINE; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 0035041926     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Genetic basis of schizophrenia
2. Obesity: Preventing and managing the global epidemic: Report of a WHO consultation
3. Overweight and obesity in the United States: Prevalence and trends, 1960-1994
4. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia
5. Atypical antipsychotics, pt 2: Adverse effects, drug interactions, and costs
6. Atypical antipsychotics, pt 1: Pharmacology, pharmacokinetics, and efficacy
7. Changes in weight in patients receiving a tranquilizing drug
8. The economics of treating obesity
9. Prevalence of obesity in patients receiving depot antipsychotics
10. Cardiovascular and respiratory risk factors and symptoms among general practice patients with long-term mental illness
11. The distribution of adipose tissue in female in-patients receiving psychotropic drugs
12. Clozapine and metabolites: Concentrations in serum and clinical findings during treatment of chronically psychotic patients
13. Increasing prevalence of overweight among US adults: The National Health and Nutrition Examination Surveys, 1960 to 1991
14. The distribution of body mass index among individuals with and without schizophrenia
15. Assessment of human body composition
16. Medical evaluation of psychiatric patients, 1: Results in a state mental health system
17. Diagnosis of physical illness in psychiatric patients using Axis III and a standardized medical history
18. Physical illnesses underlying psychiatric symptoms
19. Assessing the physical health of psychiatric patients
20. Drug-produced obesity: Experiences with chlorpromazine, perphenazine and chlopenthixol
21. A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia
22. Depot fluphenazine maintenance treatment and associated weight changes
23. Weight gain and prolactin levels in patients on long-term antipsychotic medication: A double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate
24. Clozapine-induced weight gain: Prevalence and clinical relevance
25. Differential effect of clozapine on weight: A controlled study
26. Novel antipsychotics: Comparison of weight gain liabilities
27. Antipsychotic-induced weight gain: A comprehensive research synthesis
28. Clozapine and weight gain
29. Predicted effects of small decreases in energy expenditure on weight gain in adult women
30. Ziprasidone: A novel antipsychotic with unique pharmacology and therapeutic potential
31. Dosing the antipsychotic medication olanzapine
32. Effect of long-term olanzapine treatment on weight change in schizophrenia
33. Risperidone in the treatment of schizophrenia
34. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
35. Risperidone vs haloperidol: Prevention of relapse in schizophrenia
36. Weight changes in patients treated with Seroquel (quetiapine)
37. Ziprasidone: Efficacy in the prevention of relapse and in the long-term treatment of negative symptoms of chronic schizophrenia
38. Deliberate overfeeding in women and men: Energy cost and composition of the weight gain
39. The pharmacology of weight gain with antipsychotics
40. Clozapine and olanzapine treatment decreases rat cortical and limbic GABA(A) receptors
41. Radioreceptor binding profile of the atypical antipsychotic olanzapine
42. 2 receptor occupancy of olanzapine in schizophrenia: A PET investigation
43. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
44. 2B receptor: Evidence for species differences
45. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors
46. Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity
47. + (GIRK) channel expressed in Xenopus oocytes
48. Pharmacological profile of antidepressants and related compounds at human monoamine transporters
49. Prolacfin and antipsychotic medications: Mechanism of action
50. 2 dopamine receptors involved?
51. Puberty modifies sulphide effects on body weight in rats
52. Sulpiride injections in the lateral hypothalamus induce feeding and drinking in rats
53. Mechanism of the body weight increase induced by systemic sulpiride
54. In vivo toxicity and pulmonary effects of promazine and chlorpromazine in rats
55. Effects of long-term administration of clozapine on body weight and food intake in rats
56. Genetic variation as a guide to drug development
57. 2C receptor
58. A multiple imputation strategy for clinical trials with truncation of patient data
59. Clinical trials in psychiatry: Should protocol deviation censor patient data?
60. Attitude of family to neuroleptics
61. Differing side effect burden with newer antipsychotics
62. Olanzapine: Weight gain and therapeutic efficacy
63. A study of weight reducing diets in psychiatric in-patients
64. Intensive treatment of psychotic behavior by stimulus satiation and food reinforcement
65. Rapid treatment of gross obesity by operant techniques
66. Behavior modification of overeating in a psychiatric population
67. Weight loss with psychiatric residents in a behavioral self control program
68. Amantadine in the treatment of neuroendocrine side effects of neuroleptics
69. An open clinical trial of fenfluramine in chronic schizophrenia: A pilot study
70. A clinical trial of the efficacy and acceptability of D-fenflurarnine in the treatment of neuroleptic-induced obesity
71. Weight reduction with chlorphenetermine and phenmetrazine in obese psychiatric patients during chlorpromazine therapy
72. Dexfenfluramine in psychotic patients
73. Nonpharmacologic and pharmacologic management of weight gain
74. Phentermine, psychosis, and family history
75. Phentermine and psychosis
76. Fenfluramine and psychosis
77. Delirium with manic symptoms induced by diet pills
78. Obesity: Socio-cultural perspectives
79. Societal and personal costs of obesity
80. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults: The evidence report
81. The disease burden associated with overweight and obesity
82. The relationship between body weight and mortality: A quantitative analysis of combined information from existing studies
83. Annual deaths attributable to obesity in the United States
84. Weight gain as a risk factor for clinical diabetes mellitus in women
85. Hyperglycemia associated with olanzapine
86. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications
87. Novel antipsychotics and new onset diabetes
88. Weight gain and glucose metabolism with atypical antipsychotics
89. Hyperglycemia and olanzapine
90. New-onset diabetes mellitus associated with the initiation of quetiapine treatment
91. Improvement in markers of health status 6 weeks after switching from olanzapine to ziprasidone